Robert W. Baird Boosts Laboratory Co. of America (NYSE:LH) Price Target to $261.00

Laboratory Co. of America (NYSE:LHFree Report) had its price objective increased by Robert W. Baird from $258.00 to $261.00 in a report released on Monday morning, Benzinga reports. Robert W. Baird currently has an outperform rating on the medical research company’s stock.

A number of other research firms have also recently commented on LH. JPMorgan Chase & Co. dropped their price target on shares of Laboratory Co. of America from $261.00 to $243.00 and set an overweight rating for the company in a research note on Thursday, May 30th. Argus raised shares of Laboratory Co. of America from a hold rating to a buy rating and set a $250.00 price target for the company in a research note on Monday, March 25th. StockNews.com cut shares of Laboratory Co. of America from a buy rating to a hold rating in a research note on Tuesday, June 4th. Truist Financial dropped their price target on shares of Laboratory Co. of America from $270.00 to $255.00 and set a buy rating for the company in a research note on Friday, April 26th. Finally, Barclays dropped their price target on shares of Laboratory Co. of America from $234.00 to $213.00 and set an equal weight rating for the company in a research note on Friday, April 26th. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of Moderate Buy and an average price target of $241.29.

View Our Latest Stock Analysis on LH

Laboratory Co. of America Stock Performance

Shares of NYSE:LH opened at $200.40 on Monday. Laboratory Co. of America has a 52 week low of $191.97 and a 52 week high of $234.09. The stock has a market capitalization of $16.89 billion, a P/E ratio of 40.32, a PEG ratio of 1.53 and a beta of 1.05. The firm has a fifty day simple moving average of $202.22 and a two-hundred day simple moving average of $211.86. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39.

Laboratory Co. of America (NYSE:LHGet Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business had revenue of $3.18 billion during the quarter, compared to analysts’ expectations of $3.12 billion. During the same period last year, the company posted $3.82 EPS. The business’s revenue was up 4.6% on a year-over-year basis. On average, analysts expect that Laboratory Co. of America will post 14.87 earnings per share for the current fiscal year.

Insider Transactions at Laboratory Co. of America

In other news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $210.83, for a total value of $421,660.00. Following the completion of the sale, the executive vice president now owns 5,637 shares of the company’s stock, valued at approximately $1,188,448.71. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, EVP Der Vaart Sandra D. Van sold 2,000 shares of the stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $210.83, for a total transaction of $421,660.00. Following the completion of the sale, the executive vice president now owns 5,637 shares of the company’s stock, valued at $1,188,448.71. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Kerrii B. Anderson sold 250 shares of the stock in a transaction that occurred on Tuesday, April 30th. The shares were sold at an average price of $204.13, for a total transaction of $51,032.50. Following the sale, the director now directly owns 15,972 shares of the company’s stock, valued at approximately $3,260,364.36. The disclosure for this sale can be found here. In the last quarter, insiders sold 4,939 shares of company stock valued at $1,021,078. Company insiders own 0.85% of the company’s stock.

Institutional Investors Weigh In On Laboratory Co. of America

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Mendota Financial Group LLC purchased a new position in shares of Laboratory Co. of America in the fourth quarter worth $29,000. Pathway Financial Advisers LLC purchased a new position in shares of Laboratory Co. of America in the first quarter worth $30,000. McClarren Financial Advisors Inc. raised its holdings in shares of Laboratory Co. of America by 313.2% in the first quarter. McClarren Financial Advisors Inc. now owns 219 shares of the medical research company’s stock worth $48,000 after buying an additional 166 shares during the last quarter. Quent Capital LLC raised its holdings in shares of Laboratory Co. of America by 88.4% in the second quarter. Quent Capital LLC now owns 260 shares of the medical research company’s stock worth $53,000 after buying an additional 122 shares during the last quarter. Finally, Bruce G. Allen Investments LLC purchased a new position in shares of Laboratory Co. of America in the fourth quarter worth $60,000. Hedge funds and other institutional investors own 95.94% of the company’s stock.

About Laboratory Co. of America

(Get Free Report)

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).

Read More

Analyst Recommendations for Laboratory Co. of America (NYSE:LH)

Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.